View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
July 2, 2020

Coronavirus company news summary – Pfizer-BioNTech announce positive data for Covid-19 vaccine – University of Oxford Covid-19 vaccine said to have right immune response

By Allie Nawrat

2 July 2020 

Pfizer and BioNTech have reported positive preliminary results from the ongoing Phase I/II clinical trial of BNT162b1, a potential Covid-19 vaccine. The results showed that the vaccine candidate could be given at a dose that was well tolerated and produced dose dependent immunogenicity.

At a UK parliamentary hearing, a researcher from the University of Oxford has said that the University’s Covid-19 vaccine candidate showed ‘the right sort of immune response’ in clinical trials. The vaccine, which has been licensed to AstraZeneca, is currently in Phase III trials on 8,000 volunteers. P

Sorrento Therapeutics has selected T-VIVA-19 as its targeted protein vaccine against Covid-19, as a result of findings from its preclinical vaccination programme. T-VIVA-19 is a recombinant fusion protein consisting of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc), which triggered antibodies against the SARS-CoV-2 protein in mice.

China National Biotec Group (CNBG) has completed construction of a new plant in Wuhan for Covid-19 vaccines, reported Reuters. The new facility, which has annual capacity of more than 100 million doses, is said to double CNBG’s capacity to over 200 million doses per year.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy